Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA3 | P34903 | 11/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 9/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 8/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8097295 | 0.85 | GABRA3 (0.44) | GABRA3GABRA2GABRA1GABRA5 | |
| SCHEMBL8096753 | 0.83 | GABRA3 (0.44) | GABRA3GABRA2GABRA1GABRA5 | |
| SCHEMBL8886770 | 0.83 | GABRA3 (0.43) | GABRA3GABRA2GABRA1GABRA5 | |
| SCHEMBL8096803 | 0.83 | GABRA3 (0.44) | GABRA3GABRA2GABRA1GABRA5 | |
| SCHEMBL8094708 | 0.81 | GABRA3 (0.46) | GABRA3GABRA2GABRA1GABRA5 | |
| SCHEMBL8103272 | 0.80 | GABRA3 (0.44) | GABRA3GABRA2GABRA1GABRA5 | |
| SCHEMBL9259795 | 0.80 | GABRA3 (0.41) | GABRA3GABRA2GABRA1GABRA5 | |
| SCHEMBL8088041 | 0.79 | GABRA3 (0.48) | GABRA3GABRA2GABRA1GABRA5 | |
| SCHEMBL8087741 | 0.78 | GABRA3 (0.41) | GABRA3GABRA2GABRA1GABRA5 | |
| SCHEMBL9444178 | 0.77 | GABRA3 (0.41) | GABRA3GABRA2GABRA1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5185446-A | Treating anxiety, sleep, seizure disorders | NEUROGEN CORPORATION (US) | 1993-02-09 | — | — | US | claimed |
| US-6013799-A | HIGHLY SELECTIVE AGONISTS, ANTAGONISTS OR INVERSE AGONISTS FOR G-AMINOBUTYRIC ACID (GABA) BRAIN RECEPTORS; USEFUL IN DIAGNOSIS/TREATMENT OF ANXIETY, SLEEP, AND SEIZURE DISORDERS, DRUG OVERDOSE, AND ALERTNESS ENHANCEMENT ALERTNESS | NEUROGEN CORPORATION (US) | 2000-01-11 | — | — | US | disclosed |
| US-5696260-A | AGONSIT, ANTAGONIST, PRODRUG; USEFUL IN DIAGNOSIS AND TREATMENT OF ANXIETY, SLEEP, SEIZURE DISORDER, OVERDOSE WITH BENZODIAZEPINE TYPE DRUGS AND ENHANCEMENT OF ALERTNESS | NEUROGEN CORPORATION (US) | 1997-12-09 | — | — | US | disclosed |
| US-5426186-A | Diagnosis, treatment of anxiety, sleep and seizure disorders, benzodiazepine overdose; enhancement of alertness | NEUROGEN CORPORATION (US) | 1995-06-20 | — | — | US | disclosed |
| EP-0547168-A1 | CERTAIN CYCLOALKYL IMIDAZOPYRIMIDINES, A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1993-06-23 | — | — | EP | disclosed |
| US-5185446-A | Treating anxiety, sleep, seizure disorders | NEUROGEN CORPORATION (US) | 1993-02-09 | — | — | US | disclosed |
| WO-1992004351-A1 | CERTAIN CYCLOALKYL IMIDAZOPYRIMIDINES, A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1992-03-19 | — | — | WO | disclosed |